Pulse Biosciences, Inc.
Financials
Valuation Metrics
Pulse Biosciences, Inc.'s Market Cap is $3.84B. At end of 2025 it was $925M. Ranked #1598 of 3,121 in US market (top 51%), #565 of 1,463 on NASDAQ (top 39%), #97 of 205 in Health Care Equipment & Services (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.84B | US#1,598/3,121 Sec#97/205 |
| Revenue | $1M | US#2,875/3,121 Sec#199/205 |
| Net Income | $-80M | US—/3,121 Sec—/205 |
| Total Assets | $116M | US#3,055/3,121 Sec#198/205 |
| Net Assets | $100M | US#2,813/3,121 Sec#181/205 |
| Employees | 116 | US#2,598/3,121 Sec#180/205 |
| Value | ||
| P/B | 38.61x | US#2,869/3,121 Sec#187/205 |
| P/S | 10977.57x | US#2,999/3,121 Sec#204/205 |
| FCF Yield | -1.60% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -80.46% | US#2,772/3,121 Sec#178/205 |
| ROA | -69.27% | US#3,034/3,121 Sec#201/205 |
| Op. Margin | -7007.76% | US#2,868/3,121 Sec#199/205 |
| Financial Health | ||
| Debt Ratio | 16.14% | US#186/3,121 Sec#17/205 |
| Total Debt | $7M | US#2,877/3,121 Sec#191/205 |
| FCF | $-61M | US#2,551/3,121 Sec#182/205 |
| Cash | $102M | US#2,223/3,121 Sec#136/205 |
| Current Ratio | 9.63x | US#270/3,121 Sec#10/205 |
| Performance | ||
| 1Y Return | 190.87% | US#62/3,121 Sec#7/205 |
| 1M Return | 14.57% | US#244/3,121 Sec#35/205 |
| From 52W High | -8.54% | US#1,051/3,121 Sec#80/205 |
| 1Y MDD | -36.51% | US#1,836/3,121 Sec#101/205 |
| Trading | ||
| Volume | 790,906 shares | US#1,908/3,121 Sec#131/205 |
| Trading Value | $42M | US#1,629/3,121 Sec#115/205 |
| Per Share | ||
| EPS | $-1.12 | US—/3,121 Sec—/205 |
| BPS | $1.40 | US#2,644/3,121 Sec#174/205 |
Company Info
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.